Abstract
It is now exactly 100 years ago (1908) that Paul Ehrlich, who is regarded as the inventor of the concept of targeted therapy, received the Nobel Prize for Medicine. His initial perception leading to this theory was derived from observations that certain substances are capable of selectively staining either tissues or microorganisms. These observations culminated in the discovery of the inorganic mercury compound arsphenamine (Salvarsan®) by Sahachiro Hata in the laboratory of Paul Ehrlich. Salvarsan® might be regarded as the first effective “targeted” treatment for syphilis at that time. Tamoxifen (Nolvadex®), an anti-estrogen, which was introduced in the early 1970s, was one of the first rationally designed targeted anti-tumour drugs. Since the 1970s a dramatic development of new molecular technologies occurred, culminating, for example, into the Human Genome Project and the public availability of various gene and protein databases, such as the Cancer Genome Anatomy Program established by the National Cancer Institute. Genomics, proteomics, structural genomics, transcriptomics, and high-throughput screening technologies for identification of targeted drugs are now available, which were almost unimaginable only a few years ago. Over 500 kinases are known of which about 250 have been cloned and are available to directly evaluate the activity of novel drug candidates. These technologies in conjunction with bio-informatic and chemical tools allow us to design novel molecules, and consequently tailor drug therapy to specific targets within tumours.
Keywords: Molecular targeted therapies, monoclonal antibodies, tyrosine kinase inhibitors, small molecules, oncology, hematology
Current Pharmaceutical Design
Title: Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Volume: 15 Issue: 2
Author(s): Gabriela Kornek and Edgar Selzer
Affiliation:
Keywords: Molecular targeted therapies, monoclonal antibodies, tyrosine kinase inhibitors, small molecules, oncology, hematology
Abstract: It is now exactly 100 years ago (1908) that Paul Ehrlich, who is regarded as the inventor of the concept of targeted therapy, received the Nobel Prize for Medicine. His initial perception leading to this theory was derived from observations that certain substances are capable of selectively staining either tissues or microorganisms. These observations culminated in the discovery of the inorganic mercury compound arsphenamine (Salvarsan®) by Sahachiro Hata in the laboratory of Paul Ehrlich. Salvarsan® might be regarded as the first effective “targeted” treatment for syphilis at that time. Tamoxifen (Nolvadex®), an anti-estrogen, which was introduced in the early 1970s, was one of the first rationally designed targeted anti-tumour drugs. Since the 1970s a dramatic development of new molecular technologies occurred, culminating, for example, into the Human Genome Project and the public availability of various gene and protein databases, such as the Cancer Genome Anatomy Program established by the National Cancer Institute. Genomics, proteomics, structural genomics, transcriptomics, and high-throughput screening technologies for identification of targeted drugs are now available, which were almost unimaginable only a few years ago. Over 500 kinases are known of which about 250 have been cloned and are available to directly evaluate the activity of novel drug candidates. These technologies in conjunction with bio-informatic and chemical tools allow us to design novel molecules, and consequently tailor drug therapy to specific targets within tumours.
Export Options
About this article
Cite this article as:
Kornek Gabriela and Selzer Edgar, Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel, Current Pharmaceutical Design 2009; 15 (2) . https://dx.doi.org/10.2174/138161209787002906
DOI https://dx.doi.org/10.2174/138161209787002906 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multiple Sclerosis: Current and Future Treatment Options
Endocrine, Metabolic & Immune Disorders - Drug Targets Decreasing Systemic Toxicity Via Transdermal Delivery of Anticancer Drugs
Current Drug Metabolism Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)
Current Vascular Pharmacology ACE2 and Diabetic Complications
Current Pharmaceutical Design Resident Cardiac Stem Cells
Current Pharmaceutical Design Role of Antioxidants in Redox Regulation of Diabetic Cardiovascular Complications
Current Pharmaceutical Biotechnology Natural Polyphenols and Cardioprotection
Mini-Reviews in Medicinal Chemistry Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Epidermolysis Bullosa: The Pediatricians Role
Current Pediatric Reviews Relationship of High-Sensitivity C-Reactive Protein Concentrations and Systolic Heart Failure
Current Vascular Pharmacology Complex Inheritance for Susceptibility to Sudden Cardiac Death
Current Pharmaceutical Design Current Status of Anti-Picornavirus Therapies
Current Pharmaceutical Design Metabolic Features of Alcoholic Liver Disease
Reviews on Recent Clinical Trials Prophylaxis of Cancer
Current Cancer Therapy Reviews Recent Patents on Oxidative Stress-Related Biomarkers in Chronic Heart Failure: The Central Role of Endothelium and Myeloperoxidase
Recent Patents on Biomarkers A Review on Electrocardiographic Changes in Diabetic Patients
Current Diabetes Reviews Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
Current Pharmaceutical Design